Mirogabalin for central neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled, phase 3 study in Asia

T Ushida, Y Katayama, Y Hiasa, M Nishihara, F Tajima… - Neurology, 2023 - AAN Enterprises
Background and Objectives Patients with spinal cord injury (SCI) commonly experience
central neuropathic pain (CNeP), which is challenging to treat. Mirogabalin is effective for …
被引用次数：16 相关文章

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.

T Ushida, Y Katayama, Y Hiasa, M Nishihara, F Tajima… - Neurology, 2022 - europepmc.org
Methods This randomized, double-blind, placebo-controlled, phase 3 study investigated
mirogabalin efficacy and safety for the treatment of CNeP in patients with traumatic SCI …

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia

T Ushida, Y Katayama, Y Hiasa, M Nishihara, F Tajima… - Neurology, 2023 - AAN Enterprises
Background and Objectives Patients with spinal cord injury (SCI) commonly experience
central neuropathic pain (CNeP), which is challenging to treat. Mirogabalin is effective for …
[HTML] nih.gov

[HTML][HTML] Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia

T Ushida, Y Katayama, Y Hiasa, M Nishihara, F Tajima… - Neurology, 2023 - ncbi.nlm.nih.gov
Methods This randomized, double-blind, placebo-controlled, phase 3 study investigated
mirogabalin efficacy and safety for the treatment of CNeP in patients with traumatic SCI …

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia

T Ushida, Y Katayama, Y Hiasa, M Nishihara… - …, 2023 - ingentaconnect.com
Background and Objectives Patients with spinal cord injury (SCI) commonly experience
central neuropathic pain (CNeP), which is challenging to treat. Mirogabalin is effective for …

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia

T Ushida, Y Katayama, Y Hiasa, M Nishihara… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background and objectives Patients with spinal cord injury (SCI) commonly experience
central neuropathic pain (CNeP), which is challenging to treat. Mirogabalin is effective for …

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.

T Ushida, Y Katayama, Y Hiasa, M Nishihara, F Tajima… - Neurology, 2022 - europepmc.org
Methods This randomized, double-blind, placebo-controlled, phase 3 study investigated
mirogabalin efficacy and safety for treatment of CNeP in patients with traumatic SCI. Adult …